A5055896456- Cancer therapeutics and mechanisms
- Glioma Diagnosis and Treatment
- Neurogenesis and neuroplasticity mechanisms
- DNA Repair Mechanisms
- Epilepsy research and treatment
- Neuroblastoma Research and Treatments
- Nuclear Physics and Applications
- Functional Brain Connectivity Studies
- Medical Imaging Techniques and Applications
- Advanced MRI Techniques and Applications
- Cell Image Analysis Techniques
- Lung Cancer Research Studies
- EEG and Brain-Computer Interfaces
- Ultrasound Imaging and Elastography
- Nanoplatforms for cancer theranostics
- Multiple Sclerosis Research Studies
- PARP inhibition in cancer therapy
- Optical Coherence Tomography Applications
- Neuroendocrine Tumor Research Advances
- Advanced Fluorescence Microscopy Techniques
- Advanced Neuroimaging Techniques and Applications
Children's National
2019
Johnson & Johnson (United States)
2014
Case Western Reserve University
2009-2012
Destruction or changes associated with myelin membranes in the CNS play a key role pathogenesis of multiple sclerosis and other related neurodegenerative disorders. A long-standing goal has been to detect quantify content vivo . For this reason, we have developed myelin-imaging technique based on positron emission tomography (PET). PET is quantitative imaging modality that widely used clinical settings for direct assessment biological processes at molecular level. However, lack probes...
Abstract Objectives: To directly quantify abasic sites induced by DNA-targeted chemotherapeutic agents for in vivo studies of base excision repair pathway. Background: Current cancer treatments rely heavily on to induce cytotoxic DNA damages and programmed cell death ancer cells. However, the efficacy such as temozolomide is often compromised intrinsic cellular responses (BER). Previous have shown that BER pathway results formation or apurinic/apyrimidinic (AP) inhibition AP leads...
Abstract Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE has shown great treatment efficacy in patients well-differentiated metastatic neuroendocrine tumors and a size reduction of ~20% for lesions <3 cm size. We present 66-year-old man pancreatic carcinoma, who had rapidly growing nodal conglomerate, which measured close to 10 After only 2 cycles PRRT Lu-DOTATATE, the conglomerate striking greater than 75%. This case highlights potential aggressive neoplasms.